ARTICLE | Company News
University of Tokyo, Qiagen deal
August 18, 2014 7:00 AM UTC
The university granted Qiagen exclusive, worldwide rights to splicing factor 3B subunit 1 (SF3B1). Qiagen said SF3B1 mutation status is a biomarker for prognosis in patients with myelodysplastic synd...